Shire Viropharma Inc  

(Public, NASDAQ:VPHM)   Watch this stock  
Find more results for VPHM
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 23.13 - 50.01
Open     -
Vol. 0.00
Mkt cap 3.30B
P/E     -
Div/yield     -
EPS -0.97
Shares 65.86M
Beta 2.14
Inst. own 108%

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin 3.70% 1.31%
Operating margin 9.46% 7.79%
EBITD margin - 16.72%
Return on average assets 1.49% 0.44%
Return on average equity 2.34% 0.68%
Employees 410 -
CDP Score - -


730 Stockton Dr
EXTON, PA 19341-1171
United States - Map
+1-610-4587300 (Phone)
+1-610-4587380 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ViroPharma Incorporated (ViroPharma) is biotechnology company. The Company is engaged in the development and commercialization of solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options including therapeutics for rare and orphan diseases. Its product development portfolio is focused on four programs: inryze (C1 esterase inhibitor [human]) for management of hereditary angioedema, maribavir for cytomegalovirus (CMV) infection, VP 20621 for the management of C. difficile-associated diarrhea (CDAD) and VP20629, which the Company expects to develop for the treatment of Friedreich's Ataxia. Its product development portfolio is focused on: C1 esterase inhibitor [human], maribavir for cytomegalovirus (CMV) infection, VP20621 (prevention of recurrent CDAD) and VP20629 (treatment of Friedreich's Ataxia). On January 23, 2014, Shire Plc completed tender offer for 79.5% of ViroPharma Inc.